Techniques for generating and utilizing adult hepatocyte organoids are described. An example method includes generating an organoid by culturing hepatocytes obtained from an adult donor in a hepatocyte culture medium. The hepatocyte culture medium includes a basal medium and 5 μM of a TGF-β inhibitor.
Apparatuses, systems, and methods for modular sample holders. The microscope may direct illumination light along an illumination path towards a sample and collect light from the sample along a collection path. Light along the illumination path may pass through an immersion fluid and the material of the sample holder to reach the sample. Light along collection path may pass through the material of the sample holder and the immersion fluid. The sample holder may have a first optical surface along the illumination path which is generally perpendicular to an optical axis of the illumination path. The sample holder may have a second optical surface along the collection path which is generally perpendicular to an optical axis of the collection path. The sample holder may be modular. The sample holder may contain the sample in an enclosed channel.
Extendable and flexible drive shaft members and drive shaft assemblies include circumferentially distributed anisotropic mechanisms configured to accommodate extension and flexure. A drive shaft member includes anisotropic mechanisms that are interconnected and distributed circumferentially around a longitudinal centerline of the drive shaft member. Each of the anisotropic mechanisms is configured to accommodate extension of the anisotropic mechanism parallel to the longitudinal centerline. The anisotropic mechanisms combine to transmit a torque along the longitudinal centerline.
High-throughput methods for screening candidate DNA sequences for functionality as genetic insulators in plant genetic environments, as well as genetic insulators identified by the methods and plants that include the genetic insulators as transgenic elements. Genetic insulators can be cloned with transgenes, and introduced to plant cells, tissues, and organisms, for tighter control of transgene expression.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Downloadable software, namely in molecular modeling of protein structures Software design for the purposes of molecular modeling of protein structures.
Seattle Children's Hospital d/b/a/ Seattle Children’s Research Institute (USA)
Inventor
Von Saint Andre-Von Arnim, Amelie
Diblasi, Robert Mariano
Poli, Jonathan Arthur
Sonaike, Ibukun
Yanay, Ofer
Vamos, Andrew
Abstract
A system includes a container configured to contain a liquid. The system also includes a tubing apparatus having a first port configured for connection to a gas source, a second port configured for connection to a patient interface, and a third port configured for submersion within the liquid. The system also includes an actuator configured to move the third port vertically within the container. A method includes flowing gas into the first port of the tubing apparatus to the patient interface via the second port of the tubing apparatus. The method also includes moving the third port of the tubing apparatus vertically within the container such that an amount of the liquid in the container that is above the third port changes, thereby changing a pressure at the patient interface.
Compositions, nucleic acid molecules and methods for inducing retinal regeneration and reprogramming of Müller glia (MG) into retinal ganglion cells in a subject are described. Developmental retinal ganglion cell (RGC) transcription factors Pou4f2 and Islet1 increase the Ascl1-induced neurogenic capacity of MG. The combination of Ascl1, Pou4f2 and Islet1 stimulates MG to generate bipolar cells and RGC-like neurons. Likewise, the transcription factor Onecut1, which is expressed in developing retinal cells, but not in MG, induces MG to generate RCG-like cells. Additional transcription factors that can be used include Irx2, Irx5, Neurod2, Ebf1, and Tcf3. MG-derived RGCs can exhibit action potentials in vivo, and display chromatin profiles similar to developing RGCs.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Polypeptides having an amino acid sequence at least 50% identical to, and identical at least at one identified interface position, to the amino acid sequence selected from the group consisting of SEQ ID NO: 1-44, and polypeptides having an amino acid sequence at least 50% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 45-58, are provided, as well as fusion proteins thereof, nanoparticles thereof, and methods for treating or limiting development of an infection.
e.g.e.g., dNTPs that differ chemically or physically from canonical dNTPs), in place of canonical dNTPs, that are incorporated into copies of the target sequences in place of canonical dNTPs. Due to the presence of the analog dNTPs in the copy sequences, the copy sequences exhibit different electrical signatures compared with the target sequences and can be used for improving confidence in base-calling and reducing the complexity of the sequencing problem.
A ram accelerator for accelerating a projectile is provided. The ram accelerator includes a first tube body having a first projectile bore, a second tube body having a second projectile bore axially aligned with the first projectile bore, and a baffle positioned between and operably coupling the first and second tube bodies. The baffle can have an annular baffle wall defining a central bore that is axially aligned with the first and second projectile bores, and a chamber arranged adjacent to the annular baffle wall. The chamber can extend radially outward from the central bore and the annular baffle wall can be configured to sweep a combustion wave relative to the projectile to prevent the combustion wave from traveling ahead of the projectile, leading to an unstart mechanism of the projectile in the ram accelerator.
Disclosed are protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (“off”) state, until combined with a second designed polypeptide called the key, which induces a conformational change that activates (“on”) the bioactive peptide or binding domain, components of such protein switches, and their use.
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Eyeglasses are disclosed that include eyeglass frames and a pair of ophthalmic lenses mounted in the frames. The lenses include a dot pattern distributed across each lens, the dot pattern including an array of dots spaced apart by a distance of 1 mm or less, each dot having a maximum dimension of 0.3 mm or less, the dot pattern including a clear aperture free of dots having a maximum dimension of more than 1 mm, the clear aperture being aligned with a viewing axis of a wearer of the pair of eyeglasses.
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
Use of 4-(Propan-2-yl)-N-(pyridin-4-yl)benzamide (C15H16N2O) and similar compounds to treat pain and reduce the aversiveness of negative stimuli is described. The treatments can alleviate pain, anxiety, and depression. Such treatment may reduce the perception of pain or experience of an aversive reaction to a stimulus. The treatments can activate particular portions of the brain region, such as a subpallium or a telencephalic region.
A61K 38/03 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
Conditionally active receptor agonists that, when activated, bind to IL-2 receptor βc heterodimer (IL-2Rβc), IL-4 receptor αcheterodimer (IL-4Rαc), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are components of the conditionally active receptor agonists and methods for using the conditionally active receptor agonists.
Nalfurafine ester derivatives, formulations that include the nalfurafine ester derivatives, and methods for using the nalfurafine ester derivatives and formulations for promoting stress-resilience.
Techniques described herein are directed to performing error correction for enhanced aerospace safety and navigation. For example, a carrier board used in a sensor pod system for a vehicle can include a feedback bus, a control output bus, and a processing device. the feedback bus can receive inputs from interface boards. The control output bus can provide outputs to the interface boards. The processing device can control a serial communications module that can manage operation of the feedback bus and the control output bus. The processing device can also implement an error correction system that can analyze sensor parameters received over the feedback bus. The error correction system can generate analyzed output including error corrections for the sensor parameters for outputting by the control output bus. The error correction system may determine, based on the analyzed sensor parameters, error types associated with errors with the inputs from the interface boards.
G01C 25/00 - Manufacturing, calibrating, cleaning, or repairing instruments or devices referred to in the other groups of this subclass
H04N 7/035 - Circuits for the digital non-picture data signal, e.g. for slicing of the data signal, for regeneration of the data-clock signal, for error detection or correction of the data signal
G01D 3/036 - Measuring arrangements with provision for the special purposes referred to in the subgroups of this group mitigating undesired influences, e.g. temperature, pressure on measuring arrangements themselves
G01D 5/244 - Mechanical means for transferring the output of a sensing memberMeans for converting the output of a sensing member to another variable where the form or nature of the sensing member does not constrain the means for convertingTransducers not specially adapted for a specific variable using electric or magnetic means influencing characteristics of pulses or pulse trainsMechanical means for transferring the output of a sensing memberMeans for converting the output of a sensing member to another variable where the form or nature of the sensing member does not constrain the means for convertingTransducers not specially adapted for a specific variable using electric or magnetic means generating pulses or pulse trains
G01D 18/00 - Testing or calibrating apparatus or arrangements provided for in groups
B64D 45/00 - Aircraft indicators or protectors not otherwise provided for
G01C 23/00 - Combined instruments indicating more than one navigational value, e.g. for aircraftCombined measuring devices for measuring two or more variables of movement, e.g. distance, speed or acceleration
G06N 3/044 - Recurrent networks, e.g. Hopfield networks
G06T 7/80 - Analysis of captured images to determine intrinsic or extrinsic camera parameters, i.e. camera calibration
Flat-band meta-optics for efficient photodetectors, and associated systems and methods are described. In one embodiment, a meta-optics photodetector that is configured for detecting incoming light includes a patterned structure configured for illumination by incoming light. The patterned structure is patterned at a sub-wavelength scale. The meta-optics photodetector also includes an absorber configured for generating electrical charges in response to incoming light. A p-n junction is coupled to the absorber and configured for carrying away the electrical charges as an electrical signal.
The present disclosure provides a device comprising a first connector including a first elongated hollow member configured to be positioned at least partially within a lumen of a proximal portion of a tube. The first connector provides a clamping force to the proximal portion of the tube. The device also includes a second connector configured to be removably coupled to the first connector. The second connector including a second elongated hollow member configured to be positioned at least partially within a lumen of a distal portion of the tube. The proximal portion of the tube is separated from the distal portion of the tube when the first connector is disconnected from the second connector, and the lumen of the proximal portion of the tube is fluidically connected with the lumen of the distal portion of the tube when the first connector is removably coupled to the second connector.
Alpha-sheet polypeptide multimers, and polypeptides for making multimers, compositions and medical devices including them, and their use for treating and diagnosing amyloid diseases or amyloid-associated diseases are disclosed.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
22.
PROTECTIVE MONOCLONAL ANTIBODIES TO PSEUDOMONAS AERUGINOSA
SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (USA)
Inventor
Pepper Pew, Marion
Takehara, Kennidy
Thouvenel, Christopher
Rawlings, David J.
Hale, Malika Rose
Abstract
aeruginosa aeruginosaP.aeruginosaaeruginosa. The binding proteins or antibodies or derivatives thereof disclosed herein have a high affinity to a wide range of PcrV epitopes. In an embodiment, the binding proteins disclosed herein are effective in limiting a PA infection.
A system for detecting a biological target in a sample, including a sensor comprised of single-walled nanotubes coating a sample substrate, where the sensor includes a sensing electrode and a control electrode, and an analyzer configured to accept the sensor including a controller configured to measure a resistance of the sensing electrode and a resistance of the control electrode and compare the resistance of the sensing electrode to the resistance of the control electrode. Additionally, a method of detecting a biological target with the system including placing a sample into an analyzer, inserting a sensor made of single-walled carbon nanotubes into the analyzer, wherein the sensor includes a sensing electrode and a control electrode, submerging the sensing electrode into the sample, submerging the sensing electrode into a washing solution, measuring the resistance of the sensing electrode and the control electrode, and comparing the resistances.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventor
Silva Manzano, Daniel Adriano
Yu, Shawn
Ulge, Umut
Baker, David
Garcia, Kenan Christopher
Spangler, Jamie
Walkey, Carl
Abstract
De novo designed polypeptides that bind to IL-2 receptor βc heterodimer (IL-2Rβc), IL-4 receptor αc heterodimer (IL-4Rαc), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are methods for using and designing the polypeptides.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
Methods of uniquely labeling or barcoding molecules within a nucleus, a plurality of nuclei, a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a nucleus, a plurality of nuclei, a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs and/or cDNAs.
Apparatuses, systems, and methods are directed for the use of at least one highly flexible thermoelectric device positioned in contact with and/or adjacent to heat-emitting aircraft assembly surfaces for the purpose of harvesting and/or converting energy in the form of heat to produce an electric current used to power an aircraft component.
Present apparatuses, systems, and methods are directed to the conservation of energy expended to power devices, components, systems, etc., on an aircraft, and to power aircraft manufacturing components used in the manufacture of an aircraft in an aircraft manufacturing facility using a highly flexible thermoelectric composite device to generate electrical current by converting waste heat into electrical energy.
Zwitterionic carboxybetaine copolymers and their use in coatings to impart non-fouling and functionality to surfaces, particularly surfaces of blood-contacting medical devices.
A method of fabricating a wearable and elastically stretchable thermoelectric generator or other thermoelectric device can involve arranging thermoelectric pellets and printing a thermal insulation material alongside and/or around the thermoelectric pellets to form a core layer. The core layer can be cured, and a liquid metal can be selectively deposited on the thermoelectric pellets to form contact points. Printing conductive ink can form stretchable electrical interconnects that define connections among the thermoelectric pellets via the contact points to form an initial middle layer that includes the stretchable electrical interconnects. Printing a thermal interface material may form an initial outer layer positioned between the initial outer layer and an initial side of the core layer to form a layered assembly. The layered assembly may be inverted and receive additional printed layers building away from the core layer, such as an additional interconnect layer and an additional thermal interface layer.
H10N 10/17 - Thermoelectric devices comprising a junction of dissimilar materials, i.e. devices exhibiting Seebeck or Peltier effects operating with only the Peltier or Seebeck effects characterised by the structure or configuration of the cell or thermocouple forming the device
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
Provided is a method of operating a storage system including a host device, which includes a zone manager, and a storage device. The method includes allocating, by the zone manager, a first essential write resource, a second essential write resource, a first spare write resource, and a second spare write resource to a first logical zone, allocating, by the zone manager, a third essential write resource, a fourth essential write resource, a third spare write resource, and a fourth spare write resource to a second logical zone, and reallocating, by the zone manager, the first spare write resource and the second spare write resource to the second logical zone.
Polypeptides having an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 1-381, not including any amino acid insertions at identified loop positions, are provided that bind to II- 6R, GP130, or IL-1R, and which can be used to treat or limit development of Cytokine release syndrome and other disorders.
An intrauterine system configured to be retained in a uterus of a patient, the intrauterine system including a delivery system configured to deliver one or more active compounds, where the one or more active compounds have non-systemic extrauterine biological targets. Further, a method of using the intrauterine system, including retaining the intrauterine system in a uterus, and delivering the one or more active compounds to non-systemic extrauterine biological targets in the lower female reproductive tract (LFRT) or the rectum.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Polypeptides are disclosed having an amino acid sequence at least 50% identical to the amino acid sequence of SEQ ID NO:1, wherein, relative to SEQ ID NO:1, residue 43 is I, residue 95 is Q, and residue 128 is L, fusion proteins thereof, kits thereof, and methods for using the polypeptides for treating a disorder associated with cortisol, or for detecting cortisol in a biological sample.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Provided herein are compositions and methods directed toward the discovery of improved methods for generating deoxyATP (dATP) in cells that can be delivered to a graft site in the heart to enhance cardiac function.
Various implementations described herein relate to devices, systems, and methods for inducing and/or causing cellular migration and uses thereof. Implementations described herein can be used to cause a portion of a cell population to migrate in response to a differential stimulus. Implementations described herein can be used to isolate and characterize the portion of the cell population. Implementations described herein can be used for research, diagnostic, or therapeutic purposes.
A flat nanophotonic computational camera, which employs an array of skewed lenslets (meta-optics) and a learned reconstruction approach is disclosed herein. The optical array is embedded on a metasurface that with a height of approximately one micron, is flat and sits on the sensor cover glass at approximately 2.5 mm focal distance from the sensor. A differentiable optimization method continuously samples over the visible spectrum and factorizes the optical modulation for different incident fields into individual lenses. A megapizel image is reconstructed from a flat imager with a learned probabilistic reconstruction method that employs a generative diffusion model to sample an implicit prior. A method for acquiring paired captured training data in varying illumination conditions is proposed. The proposed flat camera design is assessed in simulation and with an experimental prototype, validating that the method is capable of recovering images from diverse scenes in broadband with a single nanophotonic layer.
The invention provides isolated polypeptides, fusion proteins, isolated nucleic acid molecules, nucleic acid vectors, host cells, nanostructures, composite nanostructures, and pharmaceutical compositions. The invention further provides methods of treating a disease or disorder, medical uses, and uses involving said products of the invention. The invention further provides methods of forming a nanostructure and methods of forming a composite nanostructure. The isolated polypeptides and fusion proteins have the ability to form a nanostructure in the presence of ATP.
In some embodiments, a method of controlling speed of an ego vehicle in a vehicle platoon is provided. Cooperative adaptive cruise control (CACC) commands based on at least one of a vehicle-to-vehicle communication control received from a preceding vehicle and a feedback control based on a sensor output of a long-range sensor of the ego vehicle are provided to a speed controller. In response to detecting an occluded state, a minimum spacing value and a minimum relative velocity value between the ego vehicle and the preceding vehicle are determined based on information received before the detection of the occluded state; a safety speed based on the minimum spacing value and the minimum relative velocity value is determined; and an occluded adaptive cruise control command is provided to the speed controller to maintain a speed of the ego vehicle that is less than or equal to the safety speed.
B60W 30/165 - Control of distance between vehicles, e.g. keeping a distance to preceding vehicle automatically following the path of a preceding lead vehicle, e.g. "electronic tow-bar"
B60W 10/06 - Conjoint control of vehicle sub-units of different type or different function including control of propulsion units including control of combustion engines
G08G 1/00 - Traffic control systems for road vehicles
43.
WEARABLE DEVICES FOR DETECTING EVENTS USING EXTERNAL EAR AND AMBIENT TEMPERATURE, INCLUDING EXAMPLES OF EARRINGS
In one aspect, a wearable device includes a first temperature sensor configured to be positioned to detect an external ear temperature at an ear, and a second temperature sensor configured to dangle below the ear to detect an ambient temperature. The wearable device may include a controller coupled to the first temperature sensor and the second temperature sensor. The wearable device may also include an antenna coupled to the controller, where the antenna and the controller are configured to communicate data indicative of the external ear temperature and the ambient temperature. The communicated data can then be analyzed using a computing system to determine and/or detect an event based on the data indicative of external ear temperature and the data indicative of ambient temperature.
The present disclosure features, inter alia, a cyclic multifunctional linker, including at least two cleavable moieties; at least two connecting chains connected to the at least two cleavable moieties to provide a cyclic structure; and at least two linking groups, each linking group being bonded at one end to a connecting chain and being located between two cleavable moieties, and each linking group having a second end configured to bond to crosslinkable moieties. In the cyclic multifunctional linker, each connecting chain has at least two ends, and at least two of the connecting chains are each connected at each end to a cleavable moiety.
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
45.
OLIGOMER BARCODE FOR LABELING EXTRACELLULAR VESICLES
This application relates to oligomer barcodes for labeling extracellular vesicles (EVs). The labeled extracellular vesicles can be used to monitor EV movement for research purposes and for the development of treatments in a variety of diseases and disorders.
Examples of systems, wearable devices and computing systems described herein may enroll one or more target audio sources responsive to an indication. The indication may provide a direction of the target audio source. The enrollment may utilize audio signals received during an enrollment phase. Computing systems described herein may generate target audio source signals based on subsequent audio signals, utilizing audio characteristics of the target audio source generated during enrollment. The target audio source signals may be binaural audio signals. The target audio source signals may be played back through binaural speakers such that directionality of the target audio source is preserved.
H04R 5/027 - Spatial or constructional arrangements of microphones, e.g. in dummy heads
H04S 7/00 - Indicating arrangementsControl arrangements, e.g. balance control
G01S 3/808 - Systems for determining direction or deviation from predetermined direction using transducers spaced apart and measuring phase or time difference between signals therefrom, i.e. path-difference systems
G10L 21/028 - Voice signal separating using properties of sound source
G10L 25/30 - Speech or voice analysis techniques not restricted to a single one of groups characterised by the analysis technique using neural networks
H04R 1/32 - Arrangements for obtaining desired frequency or directional characteristics for obtaining desired directional characteristic only
THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
King, Neil P.
Ellis, Daniel
Dosey, Anne
Kanekiyo, Masaru
Abstract
Disclosed herein are polypeptides that include (a) a heptad motif domain comprising an amino acid sequence according to the genus (I-X1-X2-I-X3-X4-X5)n, wherein X1, X2, X3, X4, and X5 may independently be any amino acid other than proline, and wherein n can be 1-30; and (b) a second domain selected from the group consisting of (i) a polypeptide antigen, and (ii) a polypeptide component of a nanoparticle, nanoparticles including such polypeptides, and uses thereof.
Spatial light modulators and associated methods are described. In one embodiment, a spatial light modulator includes a photonic integrated circuit configured for emitting a plurality of light beams as a first waveform by a plurality of pixels. The light beams are individually controllable. The spatial light modulator also includes a meta-optic having a plurality of nanostructures configured for receiving the first waveform and aggregating the plurality of light beams as a second waveform at a surface of the meta-optic. The spatial light modulator also includes an aperture array configured for converting the second waveform into a third waveform, where the third waveform is smaller than the second waveform.
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
G02B 6/12 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
49.
METHODS, DEVICES, AND RELATED ASPECTS FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
UNIVERSITY OF WASHINGTON (USA)
Inventor
Wang, Chao
Gu, Liangcai
Chen, Xiahui
Kang, Shoukai
Ikbal, Md Ashif
Zhao, Zhi
Abstract
Provided herein are methods of detecting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) and/or other plasmonic metal nanoparticles (MNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, that binds to at least first and second epitopes of SARS-CoV-2 proteins, such as receptor-binding domain (RBDs) under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the first and second epitopes of the SARS-CoV-2 proteins in the sample to produce bound SARS-CoV-2 proteins. The methods also include detecting the SARS-CoV-2 proteins when aggregations of the bound SARS-CoV-2 proteins form with one another. Related compositions, reaction mixtures, devices, kits, and systems are also provided.
Described herein is a generalizable strategy to rapidly and irreversibly activate protein function with full spatiotemporal control. Through development of an exogenously triggerable self-assembling protein construct, bioactive proteins can be stably reassembled from non-functional split fragment pairs following exposure to a stimulus (e.g., light).
C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (USA)
Inventor
Pun, Suzie Hwang
Heinze, Clinton
Pichon, Trey
Gustafson, Joshua
Jensen, Michael C.
Abstract
Disclosed are systems for polymer-mediated activation of an engineered cell. The disclosed systems include (a) a polymer displaying a universal epitope and a moiety that specifically binds to a component of a tissue or cell of interest and (b) an engineered cell comprising (i) an engineered receptor that specifically recognizes the universal epitope via an extracellular binding domain and (ii) a transgene comprising a polynucleotide encoding a therapeutic protein, wherein the polynucleotide is operatively linked to an inducible promoter driven by an activation signal from an intracellular signaling domain of the engineered receptor upon engagement of the receptor with the universal epitope. Also disclosed are methods for delivering a therapeutic protein to the site of a tissue or cell of interest by administering the disclosed polymer and engineered cell. In some variations, the engineered cell is a chimeric antigen receptor (CAR) cell and/or the moiety binds to an extracellular matrix component. In some aspects, the system is useful in methods for treating a solid tumor cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Integrin α5β1-binding polypeptides are disclosed having an amino acid sequence at least 50% identical to the amino acid sequence selected from SEQ ID NO:1-14, or selected from SEQ ID NO:11-14, not including any insertions, wherein residues 8-10 relative to the reference polypeptide are RGD, and their use for treating cancer, vascular disease, rheumatoid arthritis, and diseases associated with pathogenic, angiogenesis.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
An electrostatic clutch includes a shaft having an electrically conductive first layer. The clutch also includes a hold attachment rotatably coupled to the shaft and a tension band having an electrically conductive second layer. The tension band is wrapped around the shaft such that a first end of the tension band is coupled to the hold attachment. The clutch includes a dielectric material disposed between the first layer and the second layer and a load attachment rotatably coupled to the shaft. The clutch is configured for an engaged mode where a voltage applied between the first layer and the second layer causes the tension band to clasp the shaft and the load attachment and the hold attachment to be rotationally locked to the shaft, and for a disengaged mode where the voltage is absent and the shaft can rotate freely with respect to the load attachment and the hold attachment.
Provided herein are isolated nucleic acids that encode a stable form of Rrm2 for the use of increasing the intracellular Rrm2 protein levels and cytosolic 2-deoxy-ATP (dATP) levels. Further provided herein are methods for treating a cardiac disease or disorder, e.g., myocardial infarction or myocardial ischemia, by administering the isolated nucleic acids, a polypeptide encoded by the isolated nucleic acids, or composition comprising the isolated nucleic acids to a subject in need thereof.
Crosslinked films having electro-optic activity, compositions and compounds for making the films, methods for making the films, and devices that include the films are disclosed.
Embodiments of the present disclosure provide compositions and methods for increasing nutrient uptake by plants and for effecting soil remediation. Embodiments of the composition and methods comprise a hydrogel bead, a microbial consortia, and a fungi, and can additionally comprise an excipient for administration of the hydrogel bead comprising the microbial consortia and the fungi, one or more seed, water, one or more nutrients, and combinations thereof. Such composition and methods have broad application to reduce fertilizer requirements and use, and to increase plant nutrient access and uptake. The composition and methods have additional application to remediate contaminated mediums such as soil contaminated with chemicals, petroleum, and explosives.
C05F 11/08 - Organic fertilisers containing added bacterial cultures, mycelia or the like
A01N 25/26 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
A01N 63/20 - BacteriaSubstances produced thereby or obtained therefrom
A01N 63/30 - Microbial fungiSubstances produced thereby or obtained therefrom
A system may control a mass spectrometer to acquire, during a plurality of acquisitions constituting an acquisition cycle, a set of mass spectra of product ions derived from precursor ions isolated based on a parallel isolation window successively positioned throughout a precursor mass-to-charge ratio (m/z) range. The precursor m/z range is divided into a plurality of isolation window units. The parallel isolation window includes, for each acquisition of the acquisition cycle, a set of isolation sub-windows corresponding to a distinct set of isolation window units of the precursor m/z range. At least two adjacent isolation sub-windows of the parallel isolation window are non-contiguous. Each isolation window unit of the precursor m/z range is analyzed at least twice during the acquisition cycle. A mass spectrum for the precursor m/z range may be generated based on the set of mass spectra acquired during the acquisition cycle.
Three to four residue non-naturally occurring macrocycle oligoamide comprising a chemotype of 3 or 4 monomer residues selected from the group consisting of a, b, c, d, e, f, g, h, I, j, k, l, m, n, o, p, q, r, s, t, u, and v monomers as defined in Table 1 are provided, and methods for design of such macrocycle oligoamides
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
C07K 4/00 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
59.
THIAZOLE DERIVATIVES AND THEIR USE AS IRE 1 INHIBITORS
The present disclosure provides compounds and compositions that are useful as partial antagonist of IRE1α RNase (PAIR) or kinase inhibiting RNase attenuator (KIRA), such as compounds of Formula (I'): or a pharmaceutically acceptable salt, enantiomer, or stereoisomer thereof, and compositions comprising a compound of Formula (I'), or a pharmaceutically acceptable salt, enantiomer, or stereoisomer thereof, and a pharmaceutically acceptable excipient, and methods of using said compounds and compositions.
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Provided herein are methods and compositions for delivering large proteins to a subject in need thereof for treatment of a disease or disorder. In certain embodiments, the methods and compositions described herein are useful in the delivery of large proteins to subjects using a protein expression system comprising at first and second AAV vector for the treatment of muscular or neuromuscular disease or disorders.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
Disclosed are methods and kits for detecting and visualizing biomolecules of interest, RNA molecules, and/or genomic loci, as well as the proteins, RNAs, or chromatin loci associated with the biomolecules of interest, RNA molecules, or genomic loci. The methods and kits can be used for elucidating molecular interactions in situ.
The invention provides methods for preparing DNA sequencing libraries by assembling short read sequencing data into longer contiguous sequences for genome assembly, full length cDNA sequencing, metagenomics, and the analysis of repetitive sequences of assembled genomes.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Present apparatuses, systems, and methods are directed to the conservation of energy expended to power devices, components, systems, etc., on an aircraft, and to power aircraft manufacturing components used in the manufacture of an aircraft in an aircraft manufacturing facility using a highly flexible thermoelectric composite device to generate electrical current by converting waste heat into electrical energy.
B60L 50/60 - Electric propulsion with power supplied within the vehicle using propulsion power supplied by batteries or fuel cells using power supplied by batteries
B60L 50/90 - Electric propulsion with power supplied within the vehicle using propulsion power supplied by specific means not covered by groups , e.g. by direct conversion of thermal nuclear energy into electricity
H10N 10/852 - Thermoelectric active materials comprising inorganic compositions comprising tellurium, selenium or sulfur
Provided are extension devices and systems, including an extending truss including a plurality of cells, each cell including a first scissor extender including a first member and a second member rotationally connected to the first member at an off-center point along a longitudinal axis of the first member, a second scissor extender connected to the first scissor extender, the second scissor extender including a first member and a second member rotationally connected to the first member, and a third scissor extender connected to the first scissor extender, the third scissor extender including a first member and a second member rotationally connected to the first member.
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (USA)
Inventor
Oh, Sewoong
Liu, Xiyang
Mahdavifar, Hessam
Jamali, Mohammad Vahid
Viswanath, Pramod
Makkuva, Ashok
Abstract
In some embodiments, a method of encoding a set of information bits to produce a codeword that encodes the set of information bits for reliable communication is provided. The set of information bits is received. The set of information bits are provided to a plurality of permutation layers separated by neural network processing layers. Each permutation layer accepts an input vector and generates a reordered output vector that is a reordering of the input vector. Each neural network processing layer accepts a vector of input values and generates a vector of output values based on a non-linear function of the vector of input values. The reordered output vector of a final permutation layer of the plurality of permutation layers is provided as the codeword. In some embodiments, a corresponding method of decoding a codeword to retrieve a set of information bits is provided.
H03M 13/21 - Non-linear codes, e.g. m-bit data word to n-bit code word [mBnB] conversion with error detection or error correction
H03M 13/00 - Coding, decoding or code conversion, for error detection or error correctionCoding theory basic assumptionsCoding boundsError probability evaluation methodsChannel modelsSimulation or testing of codes
H03M 13/37 - Decoding methods or techniques, not specific to the particular type of coding provided for in groups
66.
Highly Flexible Thermoelectric Composite Materials for Temperature Sensing in Aircraft
Apparatuses, systems, and methods are directed for the use of at least one highly flexible thermoelectric device positioned in contact with and/or adjacent to heat-emitting aircraft assembly surfaces for the purpose of harvesting and/or converting energy in the form of heat to produce an electric current used to power an aircraft component.
G01K 7/04 - Measuring temperature based on the use of electric or magnetic elements directly sensitive to heat using thermoelectric elements, e.g. thermocouples the object to be measured not forming one of the thermoelectric materials
67.
BACTERIAL CELLULOSE DERIVED NANOPARTICLES AND USES THEREOF
Various implementations described herein relate to methods and compositions for production of bacterial cellulose nanoparticles and uses thereof. According to some implementations, the size and shape of bacterial cellulose nanoparticles are controlled. The bacterial cellulose nanoparticles are linked to proteins to facilitate drug delivery, in some implementations. Various implementations described herein can be used for research, diagnostic, or therapeutic uses.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
69.
OPTIMAL DATA-DRIVEN DECISION-MAKING IN MULTI-AGENT SYSTEMS
Systems and methods for optimizing data-driven decision-making in multi-agent systems are described. The system may construct an equilibrium concept to capture multi-layer and/or k-level depth reasoning by agents. The system may determine best-response type conjectures for agents to interact with one another. In some examples, the system may include a machine or an algorithm interacting with a strategic agent (e.g., a human or an entity). The system may include methods for: (1) data-driven estimation and/or learning of conjectures and associated depth; and (2) data-driven design of algorithmic mechanisms for exploring the conjectural equilibrium (CE) space by influencing the strategic agent(s) behaviors through adaptively adjusting and estimating deployed strategies.
An autonomous miniature robot is described. The autonomous robot may include a chassis, a drive system, actuators, capacitors, a power harvesting system, and a microcontroller. The microcontroller may selectively control how the power harvesting system charges the capacitors. When the microcontroller is being powered by a first capacitor, the microcontroller directs the power harvesting system to charge a second capacitor. The second capacitor is used to send power pulses to the drive system to propel the robot. When the charge of the first capacitor falls below a threshold, the microcontroller directs the power harvesting system to charge the first capacitor. This process of switching between charging the two capacitors and controlling the drive system is iteratively repeated to create motion. The robot may include a set of power harvesting sensors (e.g., photodiodes) that can be used to direct the trajectory of the robot towards areas of higher power intensity.
H02J 7/16 - Regulation of the charging current or voltage by variation of field
B25J 5/00 - Manipulators mounted on wheels or on carriages
B60L 50/60 - Electric propulsion with power supplied within the vehicle using propulsion power supplied by batteries or fuel cells using power supplied by batteries
B60L 53/20 - Methods of charging batteries, specially adapted for electric vehiclesCharging stations or on-board charging equipment thereforExchange of energy storage elements in electric vehicles characterised by converters located in the vehicle
B60L 58/12 - Methods or circuit arrangements for monitoring or controlling batteries or fuel cells, specially adapted for electric vehicles for monitoring or controlling batteries responding to state of charge [SoC]
71.
DNA REPAIR THROUGH NANOTHERAPEUTIC DELIVERY OF NAD+ AND NAD+ PRECURSORS
Various implementations described herein relate to methods and compositions for targeted delivery of small molecules. According to some implementations, NAD+ and NAD+ precursors are encapsulated in a nanoparticle. To facilitate targeted delivery to the brain and other organs, the nanoparticle includes peptoids, or poly-N-substituted glycines. Particular implementations relate to the use of nanopeptoid-encapsulated NAD+ for treatment of acute brain injuries. Various implementations described herein can be used for research, diagnostic, or therapeutic uses.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/00 - Medicinal preparations characterised by special physical form
B82Y 40/00 - Manufacture or treatment of nanostructures
C07K 1/02 - General processes for the preparation of peptides in solution
72.
POTENT AND STABLE POLYPEPTIDE ANALOGUES VIA SERINE/THREONINE LIGATION
Modified polypeptides comprising an amino acid sequence having a lysine or derivative thereof functionalized at N6 with a seryl or threonyl group are disclosed, as are bioconjugates comprising the modified polypeptides, and methods for making the bioconjugates.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Passive grippers can be computationally generated for grasping objects. For example, a method described herein for producing a passive gripper for the object can include identifying a set of grasp configurations for the object. The method can also include selecting, from the set, a particular grasp configuration configured for performing passive engagement and disengagement with the object. Additionally, the method can include generating a template for the passive gripper based on the particular grasp configuration. The method can include fabricating the passive gripper based on the template.
Nucleic acids and expression vectors, and host cells or vesicles containing them, are provided that encode polypeptides and fusion proteins capable of forming hetero-oligomeric complexes capable of inducing membrane or vesicle fusion, and their use as delivery vehicles.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
Various implementations described herein relate to methods and compositions for delivery of small molecules to the brain. According to some implementations, small molecules are encapsulated in a nanoparticle. Small molecules include NAD+ precursors. In some implementations, the nanoparticle includes poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG). Various implementations described herein can be used for research, diagnostic, or therapeutic uses.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
An example plasma confinement system includes an inner electrode having a rounded first end that is disposed on a longitudinal axis of the plasma confinement system and an outer electrode that at least partially surrounds the inner electrode. The outer electrode includes a solid conductive shell and an electrically conductive material disposed on the solid conductive shell and on the longitudinal axis of the plasma confinement system. The electrically conductive material has a melting point within a range of 170° C to 800° C at 1 atmosphere of pressure. Related plasma confinement systems and methods are also disclosed herein.
INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (ICGEB) (Italy)
Inventor
Murry, Charles E.
Giacca, Mauro
Bortolotti, Francesca
Tsuchida, Hiroshi
Abstract
Described herein are compositions and methods related to enhancing cardiomyocyte transplant engraftment and methods of administering a transplant composition.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Embodiments of the present disclosure provide a single stranded nucleic acid construct with a predetermined number of binding sites, wherein the construct comprises a targeting domain, at least one signaling domain, and at least one splint oligonucleotide that hybridizes to complementary regions on the targeting domain and the signaling domain to form a ligation junction to link each domain to form a functional unit. The present disclosure also provides for methods of using the construct to quantify a target nucleic acid through signal intensity. In other embodiments, the disclosure provides use of the construct in multiplexed target detection methods.
Apparatuses, systems, and methods are disclosed for regulating an eversion process in everting sheath systems to avoid uncontrolled deployment of the sheath. The sheath system includes a reel and a sheath stored thereon, where the sheath is capable of everting from a retracted position to an extended position as the reel rotates about a rotational axis. The rotational characteristics of the reel are controlled by a torque mechanism operable to directly or indirectly apply a passive torque to the reel to adjust a rate at which the sheath is released from the reel as the sheath everts from the retracted position to the extended position.
A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
B25J 9/14 - Programme-controlled manipulators characterised by positioning means for manipulator elements fluid
B25J 13/08 - Controls for manipulators by means of sensing devices, e.g. viewing or touching devices
B25J 19/00 - Accessories fitted to manipulators, e.g. for monitoring, for viewingSafety devices combined with or specially adapted for use in connection with manipulators
F03G 7/06 - Mechanical-power-producing mechanisms, not otherwise provided for or using energy sources not otherwise provided for using expansion or contraction of bodies due to heating, cooling, moistening, drying, or the like
A polypeptide comprising a binder, the binder having a binding affinity to Sortilin-1 (Sort1) receptor and constructs thereof. The Sort1 binder capable of binding to the Sort1 receptor when the Sort1 receptor is in a protonated state, and wherein the polypeptide is further capable of being released from the Sort1 receptor when the Sort1 receptor is in a deprotonated state. The constructs a binder moiety and a cargo moiety, the cargo moiety linked to the binder moiety via a linker, the binder moiety being capable of binding to a Sortilin-1 (Sort1) receptor. The Sort1 binder and/or the construct comprising the Sort1 binder of use in promoting internalization a cargo, internalization of a therapeutic agent or extracellular protein degradation.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Proteins having luciferse activity are disclosed, having the secondary structure arrangement H1-L1-H2-L2-E1-L3-E2-L4-H3-L5-E3-L6-E4-L7-E5-L8-E6, wherein “H” is a helical domain, “L” is a loop domain, and “E” is a beta strand domain; wherein: (a) the H1 domain is at least 18 or 19 amino acids in length; residue 14 of the H1 domain is Y, D, or E, and residue 18 of the H1 domain is D or E: (b) the E3 domain is at least 6, 7, 8, 9, or 10 amino acids in length and residue 2 of the E3 domain is R; and (c) the E5 domain is at least 10, 11, 12, 13, or 14 amino acids in length and residue 9 of the E5 domain is H or M.
C12N 15/52 - Genes encoding for enzymes or proenzymes
C12N 15/62 - DNA sequences coding for fusion proteins
C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
82.
SYSTEMS AND METHODS FOR DETERMINING MEMORY METRICS
Embodiments of the present disclosure provide methods, systems and non-transitory computer-readable media of determining memory metrics. An example method includes: presenting a plurality of stimuli to a patient; collecting behavioral responses from the patient to the plurality of stimuli; extracting signature, using at least one mathematical model, from the behavioral responses related to memory processes; estimating, using a first computational model, a performance metric for each particular stimulus based on the extracted signature, the performance metric relates to speed of forgetting; and estimating, using a second computational model, memory metric of the patient based on the performance metrics of the stimuli.
A61B 5/16 - Devices for psychotechnicsTesting reaction times
A61B 5/375 - Electroencephalography [EEG] using biofeedback
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
An instrument includes a head and a main unit. The head includes an inlet and a first outlet on a side of the inlet. The first outlet is elongated along a first axis. The head includes a second outlet on an opposite side of the inlet. The second outlet is elongated along a second axis that forms an angle with the first axis that is between 1 degree and 120 degrees. The head includes a notch configured to receive a filter such that the filter is aligned with the inlet. The main unit includes an impeller that is configured to, when the head is attached to the main unit and the filter is positioned in the notch: move air through the first outlet and against a sample, move air through the second outlet and against the sample, and move air from the sample through the inlet and the filter.
The present disclosure is directed to polypeptides capable of cleaving gluten proteins, e.g., gliadins, nucleic acid molecules encoding the same, pharmaceutical compositions comprising the same, and methods of use thereof for treating celiac sprue disease and/or non-celiac gluten sensitivity (NCGS).
The compositions and methods described herein relate to the administration of small molecule inhibitors in combination with a genetic construct expressing KDM4D to promote cardiomyocyte proliferation.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
86.
ENDOSCOPIC SURGICAL DEVICES AND METHODS OF USING THE SAME
Apparatuses, systems, and methods are disclosed for a surgical device with suction capabilities to effectively remove fluid, tissue, and other debris from a surgical site and with a gripper for manipulating tissues and other anatomical structures during surgery. The surgical device also includes a handle having an actuator operable for controlling a position of the gripper and a suction control for adjusting a suctioning level of the device as desired, where the actuator and suction control are arranged on the handle to facilitate individual or simultaneous operation of both mechanisms.
An example method includes detecting, by a receiver of an apparatus at a reception time, a sound signal reflected by an object in an environment. The example method further includes determining, by identifying a frequency of the sound signal, a first angle in a first plane at which the object is disposed; determining a distance between the apparatus and the object based on a time delay between a transmission time of the sound signal and the reception time of the sound signal; and determining a second angle in a second plane at which the object is disposed based on a position of the receiver. A position of the object in the environment is determined based on the first angle, the distance between the apparatus and the object, and the second angle.
Photonic integrated circuits (PICs) systems and methods for writing PICs are described. In an embodiment, the PICs comprise a substrate; a phase-change material layer comprising a phase-change material disposed on the substrate, wherein the phase-change material comprises an amorphous phase subregion and a crystalline phase subregion; and an oxide layer coating the phase-change material layer. In an embodiment the phase-change material is configured to change phases between a crystalline phase and an amorphous phase upon illumination with light. In an embodiment, the phase-change material layer comprises a low-loss phase-change material layer.
G02B 6/12 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
H01L 25/16 - Assemblies consisting of a plurality of individual semiconductor or other solid-state devices the devices being of types provided for in two or more different subclasses of , , , , or , e.g. forming hybrid circuits
G02B 26/02 - Optical devices or arrangements for the control of light using movable or deformable optical elements for controlling the intensity of light
89.
NANOSTRUCTURED DIAMOND MICROPILLAR TIPS FOR USE AS SPECIMEN MOUNTS
Disclosed are micro-pillar structures that include diamond micro-tips and the preparation of diamond micro-tips. The diamond micro-tips are useful, for example, in chemical analytical measurements such as atom probe tomography.
Polypeptides that bind to asialoglycoprotein receptor (ASGPR), IGF-2R domain 11, IGF-2R, and fusion proteins thereof, that can promote extracellular protein degradation are provided, and methods for their use.
Polypeptides are provided that include an amino acid sequence at least 50% identical, not including any amino acid insertions at identified insertion sites, to the amino acid sequence selected from the group consisting of SEQ ID NO: 1-52, wherein the polypeptide is a sequence-specific DNA-binding polypeptide, fusion proteins comprising such polypeptides, nucleic acids encoding such polypeptides and fusion proteins, and expression vectors and host cells comprising such nucleic acids.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
Polypeptides are disclosed comprising an (Fc) binding domain, a helical polypeptide monomer, and an oligomer domain, polymers thereof, and uses thereof.
C07K 14/32 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bacillus (G)
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
93.
IRON OXIDE NANOPARTICLE-MEDIATED RADIATION DELIVERY FOR TARGETED CANCER TREATMENT
Method for nanoparticle-mediated deposition of radiation (NMDR) and targeted radiation therapies using a biodegradable and bioabsorbable iron oxide nanoparticle with a biocompatible coating that is effective to overcome various extra- and intra-cellular barriers and selectively accumulate in solid and metastatic tumors to improve the energy transfer of conventional radiotherapy
An example leadless pacemaker includes a housing including at least one outer surface and at least one energy storage device. The leadless pacemaker also includes at least one electrode coupled to the at least one energy storage device and configured to generate electrical pulses that are delivered to one or more chambers of the heat. The leadless pacemaker further includes at least one piezoelectric device disposed on at least a portion of the outer surface of the housing. The piezoelectric device is electrically coupled to the energy storage device. The piezoelectric device is configured to be generate electrical energy responsive to pressure changes in the heart.
Devices, systems, software, and methods are provided for treating bradykinesia with deep brain stimulation (DBS). In particular, DBS is performed with a neural recording device that records brain electrical signals from neural activity associated with intended movement of the subject and automatically adjusts deep brain stimulator settings and/or delivers electrical stimulation to the brain when pre-specified patterns of neural activity associated with the intended movement are detected. Machine learning computational models are used to detect and classify patterns of neural activity associated with intended movement. The neural signatures of "intended movement" are used to assist with DBS programming to determine therapeutic stimulation parameters that boost movement when a patient starts to prepare for movement and during movements but stop when the patient is resting.
Method of treating and/or preventing hemorrhagic shock, comprising administering to a subject in need thereof a therapeutically effective amount of a water-soluble polymer having a polymer backbone and pendant groups covalently coupled thereto that associate water on administration to the subject thereby functioning as a plasma volume expander.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 9/00 - Medicinal preparations characterised by special physical form
C08G 18/67 - Unsaturated compounds having active hydrogen
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
The technology disclosed herein relates to compositions and methods for improving the electrophysiological maturity of in vitro-differentiated cardiomyocytes. Media that promote electrophysiological maturation are described, as well as methods for the use of such media and the electrophysiologically matured cardiomyocytes in e.g., transplant and regenerative medicine procedures. The technology described herein is directed to cardiomyocyte maturation medium. Also described herein are associated compositions, kits, and matured cardiomyocytes. The cardiomyocyte maturation medium disclosed here can be used to modulate at least one electrophysiologic property of a cardiomyocyte. The electrophysiologically matured cardiomyocytes can engraft into cardiac tissue and can reduce or inhibit engraftment arrythmia in a subject.
